Price
$8.25
Increased by +0.86%
Dollar volume (20D)
29.54 M
ADR%
8.63
Earnings report date
Mar 25, 2025
Shares float
70.60 M
Shares short
23.43 M [33.20%]
Shares outstanding
71.12 M
Market cap
581.80 M
Beta
0.07
Price/earnings
N/A
20D range
7.70 10.88
50D range
5.94 11.16
200D range
5.28 11.50

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.

Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 5, 24 -0.32
Increased by +17.59%
-0.35
Increased by +8.17%
Aug 8, 24 -0.35
Decreased by -9.37%
-0.34
Decreased by -2.94%
May 14, 24 -0.34
Increased by +15.00%
-0.37
Increased by +8.11%
Mar 27, 24 -0.33
Increased by +23.26%
-0.43
Increased by +23.26%
Nov 7, 23 -0.39
Increased by +18.75%
-0.42
Increased by +7.14%
Aug 10, 23 -0.32
Increased by +23.81%
-0.46
Increased by +30.43%
May 11, 23 -0.40
Increased by +9.09%
-0.48
Increased by +16.67%
Feb 28, 23 -0.43
Increased by +24.56%
-0.50
Increased by +14.00%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 5.00 K
Decreased by -98.62%
-22.84 M
Decreased by -10.52%
Decreased by -456.90 K%
Decreased by -7.90 K%
Jun 30, 24 5.00 K
Decreased by -16.67%
-24.64 M
Decreased by -53.42%
Decreased by -492.80 K%
Decreased by -84.10%
Mar 31, 24 5.00 K
Decreased by -76.19%
-24.39 M
Decreased by -32.64%
Decreased by -487.88 K%
Decreased by -457.09%
Dec 31, 23 37.00 K
Increased by +133.64%
-31.64 M
Decreased by -56.44%
Decreased by -85.52 K%
Decreased by -565.08%
Sep 30, 23 362.00 K
Increased by +18.00 K%
-20.67 M
Increased by +12.10%
Decreased by -5.71 K%
Increased by +99.51%
Jun 30, 23 6.00 K
Decreased by -25.00%
-16.06 M
Increased by +18.96%
Decreased by -267.68 K%
Decreased by -8.05%
Mar 31, 23 21.00 K
Decreased by -34.38%
-18.39 M
Increased by +5.01%
Decreased by -87.58 K%
Decreased by -44.75%
Dec 31, 22 -110.00 K
Decreased by -103.36%
-20.23 M
Increased by +15.33%
Increased by +18.39 K%
Increased by +2.62 K%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY